RESUMEN
Our study aimed to expand tumor-infiltrating lymphocytes (TILs) from primary non-small cell lung cancers (NSCLCs) and evaluate their reactivity against tumor cells. We expanded TILs from 103 primary NSCLCs using histopathological analysis, flow cytometry, IFN-γ release assays, cell-mediated cytotoxicity assays, and in vivo efficacy tests. TIL expansion was observed in all cases, regardless of EGFR mutation status. There was also an increase in the median CD4+/CD8+ ratio during expansion. In post-rapid expansion protocol (REP) TILs, 13 out of 16 cases, including all three cases with EGFR mutations, exhibited a two-fold or greater increase in IFN-γ secretion. The cytotoxicity assay revealed enhanced tumor cell death in three of the seven cases, two of which had EGFR mutations. In vivo functional testing in a patient-derived xenograft model showed a reduction in tumor volume. The anti-tumor activity of post-REP TILs underscores their potential as a therapeutic option for advanced NSCLC, irrespective of mutation status.
Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas , Receptores ErbB , Neoplasias Pulmonares , Linfocitos Infiltrantes de Tumor , Mutación , Carcinoma de Pulmón de Células no Pequeñas/genética , Carcinoma de Pulmón de Células no Pequeñas/inmunología , Carcinoma de Pulmón de Células no Pequeñas/patología , Humanos , Linfocitos Infiltrantes de Tumor/inmunología , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/inmunología , Neoplasias Pulmonares/patología , Receptores ErbB/genética , Receptores ErbB/inmunología , Animales , Femenino , Masculino , Persona de Mediana Edad , Anciano , Ratones , Interferón gamma/genética , Interferón gamma/inmunología , AdultoRESUMEN
BACKGROUND: Adoptive transfer of in vitro expanded tumor-infiltrating lymphocytes (TILs) has been effective in regressing several types of malignant tumors. This study assessed the yield and factors influencing the successful expansion of tumor-infiltrating lymphocytes (TILs) from head and neck squamous cell carcinoma (HNSCC), along with their immune phenotypes. METHODS: TILs were expanded from 47 surgically resected HNSCC specimens and their metastasized lymph nodes. The cancer tissues were cut into small pieces (1-2 mm) and underwent initial expansion for 2 weeks. Tumor location, smoking history, stromal TIL percentage, human papillomavirus infection, and programmed death-ligand 1 score were examined for their impact on successful expansion of TILs. Expanded TILs were evaluated by flow cytometry using fluorescence-activated cell sorting. A second round of TIL expansion following the rapid expansion protocol was performed on a subset of samples with successful TIL expansion. RESULTS: TILs were successfully expanded from 36.2% samples. Failure was due to contamination (27.6%) or insufficient expansion (36.2%). Only the stromal TIL percentage was significantly associated with successful TIL expansion (p = 0.032). The stromal TIL percentage also displayed a correlation with the expanded TILs per fragment (r = 0.341, p = 0.048). On flow cytometry analysis using 13 samples with successful TIL expansion, CD4 + T cell dominancy was seen in 69.2% of cases. Effector memory T cells were the major phenotype of expanded CD4 + and CD8 + T cells in all cases. CONCLUSION: We could expand TILs from approximately one-third of HNSCC samples. TIL expansion could be applicable in HNSCC samples with diverse clinicopathological characteristics.
Asunto(s)
Neoplasias de Cabeza y Cuello , Inmunoterapia Adoptiva , Humanos , Linfocitos Infiltrantes de Tumor , Carcinoma de Células Escamosas de Cabeza y Cuello/terapia , Traslado Adoptivo , Neoplasias de Cabeza y Cuello/terapiaRESUMEN
BACKGROUND: Invossa™ (TissueGene-C) is a cell and gene therapy for osteoarthritis. It is composed of primary human chondrocytes (hChonJ cells) and irradiated human chondrocytes modified to express TGF-ß1 (hChonJb#7 cells). The hChonJ cells were isolated from a polydactyly donor, and TGF-ß1 cDNA was delivered to the cells, generating hChonJb#7 cells. Since the cells are allogeneic, the concern of immune response against cells has been raised. In this study, we investigated the immunogenicity of allogenic human chondrocyte, hChonJ cells. METHODS: The immunological properties of hChonJ cells were investigated through the analysis of surface marker expression and the effect on allogeneic T cell proliferation. Flow cytometry and RT-PCR analysis were performed to analyze the surface marker expression related to immune response, such as major histocompatibility complex (MHC) class I, class II, T cell co-stimulatory molecules and T cell co-inhibitory molecules. A mixed lymphocyte reaction (MLR) was conducted to evaluate how allogeneic T cells would respond to hChonJ cells. RESULTS: We observed that hChonJ cells did not express MHC class II and T cell co-stimulatory molecules, but expressed T cell co-inhibitory molecule PD-L2. IFN-γ treatment induced the expression of PD-L1, and up-regulated the expression of PD-L2. Also, we observed that hChonJ cells did not stimulate T cell proliferation from a MHC-mismatched donor. Further, they could suppress the proliferation of activated T cells. We also observed that the blockade of PD-L1 and/or PD-L2 with specific neutralizing antibody could lead to the restoration of allo-reactive T cell proliferation. CONCLUSIONS: We showed that hChonJ cells were not immunogenic but immunosuppressive, and that this phenomenon was mediated by co-inhibitory molecules PD-L1 and PD-L2 on hChonJ cells in a contact-dependent manner.
Asunto(s)
Condrocitos/inmunología , Tolerancia Inmunológica/fisiología , Inmunidad Celular/fisiología , Fenómenos Inmunogenéticos/fisiología , Células Cultivadas , Técnicas de Cocultivo , Citometría de Flujo/métodos , Humanos , Inmunomodulación/fisiologíaRESUMEN
BACKGROUND: A localized non-surgical delivery of allogeneic human chondrocytes (hChonJ) with irradiated genetically modified chondrocytes (hChonJb#7) expressing transforming growth factor-ß1 (TGF-ß1) showed efficacy in regenerating cartilage tissue in our pre-clinical studies and human Phase I and II clinical trials. These previous observations led us to investigate the molecular mechanisms of the cartilage regeneration. METHODS: Genetically modified TGF-ß1preprotein was evaluated by monitoring cell proliferation inhibition activity. The effect of modified TGF-ß1 on chondrocytes was evaluated based on the type II collagen mRNA levels and the amount of glycosaminoclycan (GAG) formed around chondrocytes, which are indicative markers of redifferentiated chondrocytes. Among the cartilage matrix components produced by hChonJb#7 cells, type II collagen and proteoglycan, in addition to TGF-ß1, were also tested to see if they could induce hChonJ redifferentiation. The ability of chondrocytes to attach to artificially induced defects in rabbit cartilage was tested using fluorescent markers. RESULTS: Throughout these experiments, the TGF-ß1 produced from hChonJb#7 was shown to be equally as active as the recombinant human TGF-ß1. Type II collagen and GAG production were induced in hChonJ cells by TGF-ß1 secreted from the irradiated hChonJb#7 cells when the cells were co-cultured in micro-masses. Both hChonJ and hChonJb#7 cells could attach efficiently to the defect area in the rabbit cartilage. CONCLUSIONS: This study suggests that the mixture (TG-C) of allogeneic human chondrocytes (hChonJ) and irradiated genetically modified human chondrocytes expressing TGF-ß1 (hChonJb#7) attach to the damaged cartilage area to produce type II collagen-GAG matrices by providing a continuous supply of active TGF-ß1.
Asunto(s)
Condrocitos/patología , Condrogénesis , Colágeno Tipo II/metabolismo , Glicosaminoglicanos/metabolismo , Factor de Crecimiento Transformador beta1/metabolismo , Animales , Células COS , Enfermedades de los Cartílagos/metabolismo , Enfermedades de los Cartílagos/patología , Enfermedades de los Cartílagos/terapia , Cartílago Articular/metabolismo , Cartílago Articular/patología , Cartílago Articular/cirugía , Adhesión Celular , Chlorocebus aethiops , Condrocitos/efectos de los fármacos , Condrocitos/trasplante , Condrogénesis/efectos de los fármacos , Técnicas de Cocultivo , Modelos Animales de Enfermedad , Fémur/metabolismo , Fémur/patología , Fémur/cirugía , Terapia Genética/métodos , Células Hep G2 , Humanos , Lactante , Mutación , Conejos , Regeneración , Transfección , Factor de Crecimiento Transformador beta1/genética , Factor de Crecimiento Transformador beta1/farmacología , Regulación hacia ArribaRESUMEN
BACKGROUND AIMS: The aim was to evaluate cartilage regeneration in animal models involving induced knee joint damage. Through cell-mediated gene therapy methods, a cell mixture comprising a 3:1 ratio of genetically unmodified human chondrocytes and transforming growth factor beta-1 (TGF-beta1)-secreting human chondrocytes (TG-C), generated via retroviral transduction, resulted in successful cartilage proliferation in damaged regions. METHODS: Non-clinical toxicology assessments for efficacy, biodistribution and local/systemic toxicity of single intra-articular administration of the cell mixture in mice, rabbits and goats was conducted. RESULTS: Administration of the mixture was tolerated well in all of the species. There was evidence of cartilage proliferation in rabbits and goats. As an additional precautionary step, the efficacy of TGF-beta1 secretion in irradiated human chondrocytes was also demonstrated. CONCLUSIONS: Four studies in rabbits and goats demonstrated the safety and efficacy of TG-C following direct intra-articular administration in animal models involving induced knee joint damage. Based on these pre-clinical studies authorization has been received from the USA Food and Drug Administration (FDA) to proceed with an initial phase I clinical study of TG-C for degenerative arthritis.
Asunto(s)
Trasplante de Células , Condrocitos/fisiología , Retroviridae , Transducción Genética , Factor de Crecimiento Transformador beta1/metabolismo , Animales , Cartílago/citología , Cartílago/patología , Cartílago/fisiología , Células Cultivadas , Condrocitos/citología , Técnicas de Transferencia de Gen , Cabras , Humanos , Masculino , Ratones , Ratones SCID , Conejos , Regeneración/fisiología , Retroviridae/genética , Retroviridae/metabolismo , Factor de Crecimiento Transformador beta1/genéticaRESUMEN
One of the most important factors in the production of cartilage is transforming growth factor beta1 (TGF-beta1). To obtain sustained release of TGF-beta1, a cell-mediated gene therapy technique was introduced. We infected chondrocytes with a retroviral vector carrying the TGF-beta1 gene. The single clone derivative showed sustained TGF-beta1 secretion. It also showed constitutive type II collagen expression. Whereas the TGF-beta1 protein itself is unable to induce formation of cartilage in vivo, human chondrocytes engineered to express a retroviral vector encoding TGF-beta1 showed cartilage formation in vivo when cells were injected into nude mice intradermally. These data suggest that cell-mediated gene therapy using TGF-beta1 as a transgene would be a promising treatment for osteoarthritis.
Asunto(s)
Diferenciación Celular , Condrocitos/metabolismo , Terapia Genética/métodos , Factor de Crecimiento Transformador beta/metabolismo , Animales , Cartílago Articular/efectos de los fármacos , Cartílago Articular/metabolismo , Trasplante de Células , Células Cultivadas , Condrocitos/citología , Condrocitos/efectos de los fármacos , Condrocitos/trasplante , Colágeno Tipo II/efectos de los fármacos , Colágeno Tipo II/metabolismo , Estudios de Factibilidad , Vectores Genéticos , Humanos , Ratones , Ratones Desnudos , Retroviridae/genética , Factor de Crecimiento Transformador beta/genética , Factor de Crecimiento Transformador beta/farmacología , Factor de Crecimiento Transformador beta1 , Transgenes , Trasplante HeterólogoRESUMEN
The purpose of this study was to investigate the efficacy of cartilage regeneration when using a mixture of transforming growth factor-beta1 (TGF-beta1)-producing human chondrocytes (hChon-TGF-beta1) and primary human chondrocytes (hChon) ("mixed cells"), compared with either hChon-TGF-beta1 or hChon cells alone. Specifically, mixed cells or hChon cells were first injected intradermally into the backs of immune-deficient nude mice to test the feasibility of cartilage formation in vivo. Both the mixed cells and the hChon-TGF-beta1 cells alone induced cartilage formation in nude mice, whereas hChon cells alone did not. To further test the efficacy of the cells in generating cartilage, an artificially induced partial thickness defect of the femoral condyle of a rabbit knee joint was loaded with hChon-TGF-beta1 cells with or without mixing additional untransduced hChon cells, and hyaline cartilage regeneration was observed at 4 or 6 weeks. The efficiency of complete filling of the defect and the quality of tissue generated after implanting were evaluated on the basis of a histological grading system modified from O'Driscoll et al. (J. Bone Joint Surg. 70A, 595, 1988). Significantly, mixed cells (14.2 +/- 0.9) produced significantly better results than hChon-TGF-beta1 (9.0 +/- 1.7) or hChon (8.0 +/- 1.8) cells alone. Histological and immunohistochemical staining of the newly repaired tissues produced after treatment with either mixed cells or hChon-TGF-beta1 cells alone showed hyaline cartilage- like characteristics. These results suggest that the implantation of mixed cells may be a clinically efficient method of regenerating hyaline articular cartilage.
Asunto(s)
Condrocitos/citología , Condrocitos/fisiología , Condrogénesis , Cartílago Hialino/fisiología , Factor de Crecimiento Transformador beta/biosíntesis , Animales , Células Cultivadas , Condrocitos/metabolismo , Condrocitos/trasplante , Colágeno Tipo II/metabolismo , ADN/genética , Ensayo de Inmunoadsorción Enzimática , Fémur/lesiones , Vectores Genéticos , Técnicas Histológicas , Humanos , Cartílago Hialino/lesiones , Cartílago Hialino/metabolismo , Inmunohistoquímica , Inyecciones Subcutáneas , Ratones , Ratones Desnudos , Plásmidos , Conejos , Proteínas Recombinantes/metabolismo , Retroviridae/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Factores de Tiempo , Factor de Crecimiento Transformador beta/análisis , Factor de Crecimiento Transformador beta/genética , Factor de Crecimiento Transformador beta1 , Trasplante HeterólogoRESUMEN
We have previously shown that the perforin gene locus is comprised of eight DNase I hypersensitive sites (DHS). Seven (DHS I-DHS VII) of them were CTL-specific whereas one (DHS VIII) in the second intron was expressed in a wide range of cell types. DHS VIII was highly AT-rich (75%) and was comprised of multiple sets of high mobility group (HMG)-I/Y binding site, two potential Special AT-rich Binding protein (SATB-1)-binding sites, and a long stretch of CTAT repeats, indicating that DHS VIII may relate to nuclear matrix-associated region (MAR). When DHS VIII was inserted into the perforin promoter-driven luciferase gene, it silenced the reporter gene transcription in CTLL-R8 cells in an orientation- and distance-independent manner. Moreover, this silencing effect was also observed in other promoters in a variety of non-CTL cell lines, suggesting that DHS VIII exerted a global silencing effect. Deletion analysis and gel-shift assays indicated that the silencing effect was mediated by the CTAT repeats and its binding protein called CTAT repeats-binding protein (CRBP).
Asunto(s)
Silenciador del Gen , Glicoproteínas de Membrana/genética , Animales , Linfocitos B/metabolismo , Composición de Base , Secuencia de Bases , Sitios de Unión/genética , Línea Celular , ADN/química , ADN/genética , ADN/metabolismo , Proteínas de Unión al ADN/metabolismo , Desoxirribonucleasa I , Genes Reporteros , Células HeLa , Humanos , Intrones , Luciferasas/genética , Ratones , Datos de Secuencia Molecular , Perforina , Proteínas Citotóxicas Formadoras de Poros , Linfocitos T Citotóxicos/metabolismo , Secuencias Repetidas en Tándem , Transcripción GenéticaRESUMEN
Bone morphogenetic protein 2 (BMP2) was selected as a transgene to regenerate osteoporotic bone defects after several BMPs were tested using a bone formation study in nude mice. Human chondrocytes were transduced with a BMP2-containing retroviral vector, and single clones were selected. The cells were characterized over numerous passages for growth and BMP2 expression. The single clones were irradiated and tested for viability. BMP2 expression lasted for 3 weeks before dying off completely after approximately 1 month. Irradiated and non-irradiated transduced chondrocytes successfully healed fractures in osteoporotic rats induced by ovariectomy. The osteoinducing effect of irradiated cells was better than that of their non-irradiated counterparts or a chondrocytes-only control. This study showed that delivering BMP2 from the transduced and irradiated chondrocytes could be an effective and safe method of repairing osteoporotic bone fractures.